e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Sarcoidosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
ACE and sIL2-R predict lung function improvement in sarcoidosis during methotrexate therapy
A. D. M. Vorselaars, C. H. M. Van Moorsel, P. Zanen, H. J. T. Ruven, A. Claessen, H. van Velzen-Blad, J. C. Grutters (Nieuwegein, Utrecht, Netherlands)
Source:
Annual Congress 2013 –Sarcoidosis
Session:
Sarcoidosis
Session type:
Oral Presentation
Number:
3068
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. D. M. Vorselaars, C. H. M. Van Moorsel, P. Zanen, H. J. T. Ruven, A. Claessen, H. van Velzen-Blad, J. C. Grutters (Nieuwegein, Utrecht, Netherlands). ACE and sIL2-R predict lung function improvement in sarcoidosis during methotrexate therapy. Eur Respir J 2013; 42: Suppl. 57, 3068
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Pulmonary sarcoidosis
Related content which might interest you:
Anti-inflammatory therapy for sarcoidosis patients
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Significant changes in monocyte subsets during infliximab therapy in severe sarcoidosis
Source: International Congress 2015 – Sarcoidosis: pathogenesis
Year: 2015
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Effect of baseline statin use on benefit of nintedanib
Source: International Congress 2016 – IPF treatment II
Year: 2016
Effect of pirfenidone on IPF progression
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy
Source: International Congress 2014 – ILDs 4
Year: 2014
Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Immunosuppressive treatment is not a predictor of mortality after surgical lung biopsy for interstitial lung disease
Source: International Congress 2016 – Sarcoidosis
Year: 2016
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON
Source: International Congress 2016 – IPF treatment II
Year: 2016
Severe fibrotic lung disease – How much therapy is too much therapy?
Source: Annual Congress 2008 - Clinical Grand Round - an interactive session
Year: 2008
Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD)
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Effect of baseline FVC on lung function decline with nintedanib in patients with IPF
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Surfactant protein-D level as a predictor of prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Effect of baseline composite physiologic index on benefit of nintedanib in IPF
Source: International Congress 2016 – IPF treatment I
Year: 2016
Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept